Bundibugyo Ebola Outbreak in the DRC and Rapid Vaccine Trials: WHO Allocates 70,000 Ervebo Doses for Emergency Trial
The active and highly lethal outbreak of Ebola in the Democratic Republic of the Congo (DRC), caused by the rare Bundibugyo ebolavirus species, has escalated into the second-largest Ebola outbreak in history. Because there is currently no approved vaccine specifically targeting the Bundibugyo strain, the World Health Organization (WHO) and the International Coordinating Group (ICG) on Vaccine Provision announced on August 20, 2026, a major international biosecurity intervention: the allocation of 70,000 doses of Merck's Ervebo vaccine to the DRC.
The Scientific Challenge: Testing Zaire Vaccine Against Bundibugyo Strain
Ervebo is highly effective and FDA-approved, but it was designed specifically to target the Zaire ebolavirus strain, which caused the devastating 2014–2016 West African epidemic. It is not approved for, nor is its efficacy established against, the Bundibugyo ebolavirus strain currently spreading through the DRC.
To address this critical gap, the WHO and the Coalition for Epidemic Preparedness Innovations (CEPI) are leveraging this emergency shipment to conduct a high-stakes Phase III clinical trial:
- Trial Allocation: Out of the 70,000 allocated doses, 20,000 doses are designated specifically for a randomized clinical trial in the outbreak zone to evaluate whether Ervebo can generate cross-protective immune responses or clinical protection against the Bundibugyo strain.
- Frontline Protection: The remaining 50,000 doses will be deployed to protect frontline healthcare workers and high-risk individuals in affected communities under an investigational protocol.
- Animal Data Signal: The trial is supported by emerging preclinical data from animal studies suggesting that Ervebo may elicit a degree of cross-reactive neutralizing antibodies against related filoviruses, including Bundibugyo.
Verbatim Quotes
From a WHO briefing reported on August 20, 2026:
"The Democratic Republic of the Congo will receive 70,000 Ervebo Ebola vaccine doses, including supplies for clinical research and frontline workers... with 20,000 doses for a critical trial against the Bundibugyo strain."
From a CIDRAP report on August 20, 2026:
"Today the World Health Organization (WHO) announced it has allocated 70,000 Ervebo doses for use in the Democratic Republic of Congo (DRC) to help combat... Ervebo is a vaccine targeting Ebola Zaire, the most common strain of the hemorrhagic fever, and not Bundibugyo, the strain causing the fastest-growing Ebola..."